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Background
Despite improvements in diagnosis, surgical techniques,
and multidisciplinary approaches to patient care, the
median survival of patients with metastatic gastroesopha-
geal adenocarcinoma is less than one year. Chemotherapy
is the mainstay of treatment in patients with metastatic
disease, but is associated with significant toxicity. There
is still, therefore, a significant unmet clinical need in this
patient population. Blockade of immune checkpoints is
one of the most promising novel approaches in cancer
treatment. Blocking programmed cell death ligand-1
(PD-L1) or cytotoxic T-lymphocyte-associated antigen-4
(CTLA-4) immune checkpoints with anti-PD-L1 or anti-
CTLA-4 antibodies has shown clinical promise in other
solid tumors. Durvalumab (MEDI4736) is a selective,
high affinity human IgG1 monoclonal antibody (mAb)
that blocks PD-L1 binding to programmed cell death-1
(PD-1) (IC50 0.1 nM) and CD80 (IC50 0.04 nM). Tremeli-
mumab is a selective human IgG2 mAb inhibitor of
CTLA-4, which promotes T-cell activity through CTLA-4
inhibition. Preclinical data suggest that combining immu-
notherapies may result in superior antitumor activity ver-
sus monotherapy, leading to higher and more durable
response rates and improved overall and progression-free
survival (PFS).
Methods
This is a randomized, multicenter, open-label Phase
Ib/II study to investigate the safety and antitumor activity
of durvalumab and tremelimumab, given as monotherapy
or in combination, in patients with histologically- or
cytologically-confirmed recurrent or metastatic gastric or
gastroesophageal junction adenocarcinoma who have
progressed on, or are refractory to standard regimens
(NCT02340975). The Phase Ib part of the study will
identify the doses and schedules to be used in Phase II.
In Phase II, patients will be enrolled in one of four treat-
ment arms. The objectives for Phase Ib are to assess the
safety and tolerability (primary objective) and the antitu-
mor activity (objective response rate [ORR], and PFS at
six months [PFS-6]; secondary objectives) of durvalumab
in combination with tremelimumab. The primary objec-
tives for Phase II are to assess the antitumor activity
(ORR and PFS-6) of the monotherapies and combination
therapy; the secondary objectives are to further assess
safety, tolerability, and antitumor activity (disease control
rate, duration of response, overall survival), and to inves-
tigate correlations between PD-L1 expression and clinical
activity. Exploratory objectives include evaluation of
pharmacokinetics, pharmacodynamics, and immunogeni-
city. Recruitment is ongoing, with an estimated enroll-
ment of 174 patients.
Trial registration
ClinicalTrials.gov identifier NCT02340975.
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